These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 30650200)
1. Targeting mTORC1/2 with OSI-027 inhibits proliferation and migration of keloid keratinocytes. Chen J; Liu K; Liu Y; Wang X; Zhang Z Exp Dermatol; 2019 Mar; 28(3):270-275. PubMed ID: 30650200 [TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091 [TBL] [Abstract][Full Text] [Related]
3. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells. Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051 [TBL] [Abstract][Full Text] [Related]
6. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852 [TBL] [Abstract][Full Text] [Related]
7. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909 [TBL] [Abstract][Full Text] [Related]
8. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Gupta M; Hendrickson AE; Yun SS; Han JJ; Schneider PA; Koh BD; Stenson MJ; Wellik LE; Shing JC; Peterson KL; Flatten KS; Hess AD; Smith BD; Karp JE; Barr S; Witzig TE; Kaufmann SH Blood; 2012 Jan; 119(2):476-87. PubMed ID: 22080480 [TBL] [Abstract][Full Text] [Related]
9. Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors. Melick CH; Jewell JL Biochem J; 2020 May; 477(10):1847-1863. PubMed ID: 32347294 [TBL] [Abstract][Full Text] [Related]
10. Effects of rapamycin and OSI-027 on α-SMA in lung tissue of SD rat pups with hyperoxic lung injury. Liang M; Dang H; Li Q; Huang W; Liu C Biochem Biophys Res Commun; 2021 Jun; 556():39-44. PubMed ID: 33836346 [TBL] [Abstract][Full Text] [Related]
11. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. Liu L; Luo Y; Chen L; Shen T; Xu B; Chen W; Zhou H; Han X; Huang S J Biol Chem; 2010 Dec; 285(49):38362-73. PubMed ID: 20937815 [TBL] [Abstract][Full Text] [Related]
12. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Montero JC; Chen X; Ocaña A; Pandiella A Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482 [TBL] [Abstract][Full Text] [Related]
13. Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways. Xu C; Liu C; Liu L; Zhang R; Zhang H; Chen S; Luo Y; Chen L; Huang S Neuropharmacology; 2015 Oct; 97():35-45. PubMed ID: 26002629 [TBL] [Abstract][Full Text] [Related]
14. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells. Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655 [TBL] [Abstract][Full Text] [Related]
15. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906 [TBL] [Abstract][Full Text] [Related]
16. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma. Zhang X; Wang X; Xu T; Zhong S; Shen Z Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752 [TBL] [Abstract][Full Text] [Related]
18. MTORC2 is a physiological hydrophobic motif kinase of S6 Kinase 1. Majeed ST; Majeed R; Malik AA; Andrabi KI Biochim Biophys Acta Mol Cell Res; 2023 Apr; 1870(4):119449. PubMed ID: 36858209 [TBL] [Abstract][Full Text] [Related]
19. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. Chen L; Xu B; Liu L; Liu C; Luo Y; Chen X; Barzegar M; Chung J; Huang S Oncotarget; 2015 Mar; 6(9):7136-50. PubMed ID: 25762619 [TBL] [Abstract][Full Text] [Related]
20. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells. Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]